Core 1: Biobank and Pathology

核心1：生物库和病理学-摘要/摘要 生物库和病理学核心(核心1)的主要目标是促进创新的翻译 在预防、检测和治疗肝癌方面的研究，通过提供临床和组织学良好的 描述了来自肝细胞癌患者的组织和血液样本。核心1将作为全面的 为孢子项目提供资源，总目标是集中收集、储存和分发 以及收集组织病理学/分子图谱和临床病理信息。 向MD Anderson推荐的肝细胞癌(HCC)患者。反映了发病率的上升 在肝细胞癌中，在MD Anderson寻求和接受治疗的肝细胞癌患者的数量每增加一次 从2013年的277名病人增加到2017年的580名病人，最近5年增加了2倍。堆芯 1将维护肝细胞癌的组织和血液储存库。本资料库收录的标本有：a)新鲜标本 来自手术切除的肝癌或活检标本的冷冻肿瘤和邻近肝组织；b)石蜡切片- 来自手术切除的肝癌或活检标本的包埋肿瘤和邻近肝组织；c)血液 肝细胞癌患者的样本(血清、血浆、黄褐色大衣)；d)芯针活检和细针抽吸 标本。目前，219名肝癌患者的2618份组织样本和1824名肝癌患者的血液样本 患者可以在肝脏肿瘤库中找到。在授予肝细胞癌孢子期间，核心1将 继续收集组织和血液样本，预计数量如下：切除的组织(200个 患者)、活组织检查(75名患者)和血液样本(1000名患者)。核心1将为以下项目提供病理检查 所有临床标本都将用于孢子项目，并将在必要时提供组织病理学服务。 此外，核心1将为收集的所有肝癌标本创建和维护一个数据库，使用定制的 数据库包含用于全面样品识别、表征、处理、样品/载玻片的模块 质量控制、研究组织请求、样本交易和组织样本跟踪。最后，核心1 将预测未来的需求，并填补目前还没有试剂的利基市场。其中包括：a)TMA，b) 手术切除的肿瘤和邻近肝脏的免疫图谱，以及c)开发新的临床应用-- 符合CLIA的相关测试。

Core 1: Biobank and Pathology – SUMMARY/ABSTRACT The primary objective of the Biobank and Pathology Core (Core 1) is to facilitate innovative translational research in prevention, detection and treatment of HCC, by providing clinically and histologically well- characterized tissue and blood specimens from patients with HCC. Core 1 will serve as the comprehensive resource for the SPORE projects with an overall goal of centralizing the collection, storage and distribution of biospecimens; and gathering of histopathological/molecular profiles, and clinicopathological information of patients with hepatocellular carcinoma (HCC) who are referred to MD Anderson. Reflecting the rising incidence of HCC, the number of HCC patients who sought, and received, care at MD Anderson has increased every year, from 277 patients in 2013 to 580 patients in 2017, a 2-fold increase during the most recent 5 years. Core 1 will maintain a tissue and blood repository of HCC. The specimens included in this repository are: a) Fresh frozen tumor and adjacent liver tissues from surgically resected HCCs or from biopsy samples; b) Paraffin- embedded tumor and adjacent liver tissue from surgically-resected HCCs or from biopsy specimens; c) Blood samples (serum, plasma, buffy coat) from HCC patients; d) Core needle biopsy and fine needle aspirate specimens. Currently, 2618 tissue specimens from 219 HCC patients and blood specimens from 1824 HCC patients are available in the Liver Tumor Bank. During the duration of the HCC SPORE grant, Core 1 will continue to collect tissue and blood specimens, with the following anticipated numbers: resected tissue (200 patients), biopsies (75 patients) and blood samples (1000 patients). Core 1 will provide pathological review for all clinical specimens utilized in the SPORE projects and will provide histopathological services as necessary. In addition, Core 1 will create and maintain a database for all HCC specimens collected, using a customized database with modules for comprehensive sample identification, characterization, processing, sample/slide quality control, research tissue requests, sample transactions, and tracking of tissue samples. Finally, Core 1 will anticipate future needs and fill niches for which no reagents currently exist. These include: a) TMAs, b) Immuno-profiling of surgically-resected tumors and adjacent liver, and c) Development of novel, clinically- relevant CLIA-compliant tests.